TIGIT Antibody [2F7] | SD8827

TIGIT Antibody [2F7]

Specifications

• HOST SPECIES: Llama
• SPECIES REACTIVITY: Human
• IMMUNOGEN: TIGIT antibody was raised against a recombinant protein corresponding to amino acids 22-141 of human TIGIT.
• CONJUGATE: Unconjugated
• TESTED APPLICATIONS: E, Flow, ICC, IF, IHC-P
• APPLICATION NOTE: TIGIT antibody can be used for ELISA starting at 0.1 μg/mLimmunohistochemistry starting at 10 μg/mL. For immunofluorescence start at 20 μg/mL. For flow cytometry at 1 μg/ml. For immunocytochemistry at 10μg/mL.

Properties

• PURIFICATION: TIGIT Antibody is affinity chromatography purified via Nickel column. Antibody is supplied as a His-tagged purified protein.It also contains a myc-tag for detection.
• CLONALITY: Recombinant Monoclonal
• ISOTYPE: sdAb
• PHYSICAL STATE: Liquid
• BUFFER: TIGIT Antibody is supplied in PBS.
• CONCENTRATION: 1 mg/mL
• STORAGE CONDITIONS: TIGIT antibody should be stored in working aliquots at -20˚C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Additional Info

• NCBI OFFICIAL SYMBOL: TIGIT
• ADDITIONAL NAMES: TIGIT Antibody: T-cell immunoreceptor with Ig and ITIM domains, VSIG9, VSTM3, WUCAM
• Protein Accession Number: NP_776160
• PROTEIN GI NUMBER: 256600228
• NCBI GENE ID NUMBER: 2016332
• USER NOTE: Optimal dilutions for each application to be determined by the researcher.

Background

• TIGIT Antibody: The T cell immunoreceptor with Ig and ITIM domains (TIGIT) is a member of the PVR (poliovirus receptor) family of immunoglobin proteins. It is expressed on several classes of T cells including follicular B helper T cells (TFH). TIGIT has been shown to bind PVR with high affinity; this binding is thought to assist interactions between TFH and dendritic cells to regulate T cell dependent B cell responses (1). Similar to other immune checkpoint proteins such as PD-1, TIGIT is upregulated on exhausted T cells in chronic viral infections and cancer. Blockade of both TIGIT and PD-1 pathways leads to tumor rejection in mice suggesting that it may be of therapeutic use against cancer (2).
• 1: Stanietsky N, Simic H, Arapovic J, et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc Natl Acad Sci USA 2009; 106:17858-63.
• 2: Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26:923-37.